Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on cancer therapeutics, has been named an Emerald honoree at the 2026 Pinnacle Awards for Healthcare, recognizing its innovative approach to addressing cancer drug resistance. This award underscores the importance of the company's strategy centered on resistance-modulating treatments, particularly its lead candidate ENV-105 (carotuximab), designed to inhibit tumor resistance pathways and enhance the effectiveness of existing therapies.
The Pinnacle Awards honor organizations that demonstrate excellence in healthcare innovation. For Kairos Pharma, the recognition validates its focus on one of the most pressing challenges in oncology: drug resistance. Many cancer patients initially respond to treatment but eventually relapse due to the emergence of resistant tumor cells. Kairos's approach aims to reverse this resistance by targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By inhibiting CD105, ENV-105 seeks to restore the effectiveness of standard therapies across multiple cancer types.
Kairos Pharma is currently advancing combination approaches aimed at improving durability of response across multiple cancer indications. ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. The company's use of structural biology to overcome drug resistance and immune suppression sets it apart in the oncology therapeutics landscape.
Dr. John S. Yu, CEO of Kairos Pharma, has emphasized the potential of ENV-105 to transform treatment paradigms. The Pinnacle Award highlights the promise of this approach, bringing attention to the company's efforts as it progresses through clinical development. As of the date of the announcement, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any comparable foreign regulator.
The award also shines a spotlight on the broader issue of drug resistance in cancer. According to the American Cancer Society, drug resistance is a major cause of treatment failure, contributing to the majority of cancer-related deaths. Innovations like those from Kairos Pharma could lead to more durable responses and improved survival rates.
For more information about Kairos Pharma and its pipeline, visit the company's newsroom at https://ibn.fm/KAPA. The full press release detailing the award is available at https://ibn.fm/ghPJC.
